← All trials
NCT05765006
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 24, 2023
- Primary completion
- Dec 30, 2024
- Completion date
- Dec 30, 2025
- First posted
- Mar 13, 2023
- Last posted
- Mar 15, 2023
- Enrollment
- 24
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shanghai Ming Ju Biotechnology Co., Ltd.Lead sponsor
- Huazhong University of Science and TechnologyOverall official - principal investigator
- Jiao Tong UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.